Palliative Care Outcomes in the Management of Malignant Ascites by Interventional Radiology

Refractory Malignant Ascites Clinical Trial

Official title:
Palliative Care Outcomes in the Management of Malignant Ascites by Interventional Radiology

Status Withdrawn

Clinical Trial Summary

Malignant ascites leads to significant morbidity in patients with terminal cancer. Paracentesis can provide relief, but repeat hospital visits, pain, and short duration of relief after paracentesis are detrimental to quality of life(QOL). Two devices are available as alternatives to paracentesis. The impact of either device on QOL has not fully been explored. A pilot nonrandomized trial measuring palliative care QOL and ascites symptom relief using validated survey instruments is proposed.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02477657
Study type	Observational
Source	Abramson Cancer Center of the University of Pennsylvania
Contact
Status	Withdrawn
Phase
Start date	July 2021
Completion date	July 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01852409` - Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites	Phase 1
Completed	`NCT04771676` - Intraperitoneal Injection of Oncolytic Viruses H101 for Patients With Refractory Malignant Ascites	Phase 2
Completed	`NCT02891369` - Analysis of Patients Treated With Bevacizumab Intraperitoneal for the Treatment of Refractory Malignant Ascites
Recruiting	`NCT05303844` - Oncolytic Virotherapy Plus PD-1 Inhibitor for Patients With Refractory Malignant Ascites	Phase 1